ST8SIA1: Potential Drug Target Or Biomarker (G6489)

Target Name: ST8SIA1

NCBI ID: G6489

ST8SIA1

ST8SIA1: Potential Drug Target Or Biomarker

Sialyltransferase 8 (alpha-N-acetylneuraminate: alpha-2,8-sialytransferase, GD3 synthase), also known as ST8SIA1, is a enzyme involved in the synthesis of a type of carbohydrate known as sialic acid. Sialic acid is a key component of the cell surface, and it plays a crucial role in many different cellular processes.

Research has suggested that ST8SIA1 may have potential as a drug target or biomarker. One reason for this is that ST8SIA1 is highly expressed in many different tissues and cells, including brain, pancreas, and gastrointestinal tract. Additionally, ST8SIA1 has been shown to be involved in the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In addition to its potential as a drug target, ST8SIA1 has also been shown to be a useful biomarker for certain diseases. For example, ST8SIA1 has been used as a marker for pancreatic cancer, and has been shown to be overexpressed in pancreatic cancer samples compared to matched normal tissue. Similarly, ST8SIA1 has been used as a marker for neurodegenerative diseases, and has been shown to be expressed in the brains of individuals with Alzheimer's disease and other forms of dementia.

Another potential application of ST8SIA1 is its role in the development and progression of certain autoimmune disorders. For example, ST8SIA1 has been shown to be involved in the development of multiple sclerosis, an autoimmune disorder that causes muscle weakness and stiffness. Additionally, ST8SIA1 has been shown to be involved in the development of rheumatoid arthritis, another autoimmune disorder that causes joint inflammation and pain.

In conclusion, ST8SIA1 is a highly expressed enzyme that is involved in the synthesis of a key component of the cell surface. As a result, it has potential as a drug target or biomarker for a variety of different diseases. Further research is needed to fully understand the role of ST8SIA1 in these diseases and to develop effective treatments.

Protein Name: ST8 Alpha-N-acetyl-neuraminide Alpha-2,8-sialyltransferase 1

Functions: Catalyzes the addition of sialic acid in alpha 2,8-linkage to the sialic acid moiety of the ganglioside GM3 to form ganglioside GD3; gangliosides are a subfamily of complex glycosphinglolipds that contain one or more residues of sialic acid (PubMed:7937974, PubMed:8058740, PubMed:8195250, PubMed:8631981, PubMed:8706663, PubMed:18348864, PubMed:22885356). Can catalyze the addition of a second alpha-2,8-sialic acid to GD3 to form GT3 (PubMed:8631981). Can use GM1b, GD1a and GT1b as acceptor substrates to synthesize GD1c, GT1a and GQ1b respectively (PubMed:8706663). Can synthesize unusual tetra- and pentasialylated lactosylceramide derivatives identified as GQ3 (II3Neu5Ac4-Gg2Cer) and GP3 (II3Neu5Ac5-Gg2Cer) in breast cancer cells (PubMed:22885356)

The "ST8SIA1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ST8SIA1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets